Jubilant Life Sciences launches remdesivir under brand name JUBI-R in India

Published On 2020-08-04 07:30 GMT | Update On 2020-08-04 07:30 GMT

Noida: Jubilant Life Sciences Limited, an integrated global pharmaceutical and life sciences company, has announced that its subsidiary, Jubilant Generics Limited ("Jubilant"), has launched remdesivir for injection under the brand name 'JUBI-R' in the Indian market at a price of INR 4,700 per vial of 100 mg (lyophilized injection).

The Company will make the drug available to over 1,000 hospitals providing COVID-19 treatment in India through its distribution network.

Jubilant's 24 hour helpline will enhance access to 'JUBI-R' during these pandemic times, where timely access to the drug may prove critical to treatment outcomes.

In order to increase the accessibility of 'JUBI-R' to patients below the poverty line and to front line paramedical staff, Jubilant Bhartia Foundation, a not-for-profit organisation of Jubilant Group, is launching unique programs in India aimed at the distribution of the drug.

In May 2020, Jubilant entered into a non-exclusive Licensing Agreement with Gilead Sciences, Inc. that granted it the right to register, manufacture and sell Gilead's investigational drug remdesivir in 127 countries including India.

Remdesivir is the only antiviral drug that has received Emergency Use Authorization (EUA) by the USFDA for treatment of suspected or laboratory confirmed COVID-19 in adults and children hospitalized with severe disease.

On July 20, 2020, Jubilant received approval from the Drug Controller General of India (DCGI) to manufacture and market the investigational antiviral drug remdesivir ("JUBI-R") for 100 mg/vial (lyophilized injection) for restricted emergency use in India for the treatment of severe COVID-19. 'JUBI-R' will require to be administered intravenously in a hospital setting under the supervision of a medical practitioner.

"It gives us immense satisfaction to launch 'JUBI-R' as this drug has a potential to save precious lives across the globe. We have launched the product at affordable prices and strive to make it available in sufficient quantities to meet the high demand for the drug in the Indian market and in other countries," stated Mr Shyam S. Bhartia, Chairman & Managing Director and Mr Hari S. Bhartia, Co-Chairman, Jubilant Pharma Limited. "The Company's ability to launch this product in such short timelines highlights our R&D and manufacturing capabilities and our continued commitment to provide leading healthcare solutions. Through the Jubilant Bhartia Foundation, we will distribute the drug on compassionate basis to save precious lives of people through unique programs."

Read also: Jubilant Life Sciences Gets DCGI Nod To JUBI-R For Treating COVID-19 Patients

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Jubilant Life Sciences launches remdesivir under brand name JUBI-R in India

Similar News

NPPA Panel Rejects Dr Reddy's Omez ODT Plea For Seperate Price, Finds No Therapeutic Edge

CDSCO Panel Approves Phase IV Protocol Amendment for Bristol-Myers Squibb's Mavacamten Study

Natco Pharma Mekaguda API unit gets USFDA EIR

Zydus Lifesciences receives tentative approval from USFDA for Chronic lymphocytic leukaemia drug Ibrutinib

Roche Itovebi gets European Commission nod in fight against advanced breast cancer

USFDA extends review period for GSK Blenrep in relapsed/refractory multiple myeloma

JnJ Darzalex gets European Commission nod for high-risk smouldering multiple myeloma

Lupin wins USFDA nods for Liraglutide, Glucagon Injectable Products